Rumin is a seasoned drug hunter with an expertise in biophysics, biochemistry and pharmacology. Prior to joining Volastra, Rumin served as vice president of discovery at Rafael Pharmaceuticals, a company focused on developing therapies that target altered cancer metabolism, and head of research & senior director at Eternity Bioscience, a subsidiary of Hengrui Medicine. Before Eternity, Rumin was a senior principal scientist at Merck and Schering-Plough Research Institute. Rumin received his bachelor’s in biology and microbiology from Wuhan University and his Ph.D. in biophysics and biochemistry from SUNY at Buffalo.